Cepharanthine (CEP), a plant-derived alkaloid, emerged from a phenotypic screen as a selective killer of senescent cells. It works through two parallel, non-redundant routes: suppressing PI3K/AKT survival signaling and activating the PERK-ATF4-CHOP stress pathway, which differentially induces PUMA and NOXA and triggers mitochondrial intrinsic apoptosis. In zebrafish, C. elegans, naturally aged mice and a Hutchinson-Gilford progeria mouse model, CEP reduced senescence markers and SASP levels, improved organ function and prolonged lifespan.
All of this evidence comes from cell cultures and animals; no human data exist. That matters because the senolytic field has a poor record of clean translation. Dasatinib plus quercetin and fisetin dominate the literature, yet human trials remain small and early, and many promising agents carry off-target toxicity. CEP's appeal is that it is already an approved drug in Japan for conditions such as leukopenia, giving it a known safety record, although the doses used for senolysis may differ from clinical ones. Targeting two survival pathways at once could improve selectivity, but it also raises the risk of killing healthy stressed cells, and the abstract reports no detailed toxicity data. Progeria models are also a poor proxy for normal aging, and lifespan gains in worms and fish seldom carry over to mammals. Treat this as a credible, mechanistically interesting lead, incremental rather than paradigm-shifting. Nobody should self-supplement with cepharanthine on this basis; human trials must come first.
